Admission to hospital or death within 28 days · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Resolution of symptoms · outpatients withmild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to symptom resolution · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in time to symptom resolution (absolute effect calculated for day 12) compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Quality of life, · outpatients withmild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Serious adverse events · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events compared with placebo or standard care alone (low certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · outpatients withmild disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with standard plasma (very low certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma probably leads to lower admission to hospital or death within 28 days compared with standard plasma (moderate certainty).
1 finding from 1 review
Resolution of symptoms · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in symptom resolution‐ all initial symptoms resolved compared with standard plasma (low certainty).
2 findings from 1 review
Quality of life, · outpatients withmild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events ‐ not reported · outpatients withmild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · outpatients withmild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Total studies: 8 RCTs Total Participants: 9983 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
Total studies: 13 RCTs Total Participants: 144476 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
HD‐ICS/LABA (Direct evidence; 8 RCTs; 7511 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
MD‐TRIPLE (Direct evidence; 3 RCTs; 3187 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
HD‐TRIPLE (Direct evidence; 2 RCT; 2039 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Total studies: 11 RCTs Total Participants: 13209 · Adolescent sand adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
HD‐ICS/LABA (Direct evidence; 6 RCTs; 6244 participants) · Adolescent sand adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review